Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents.

By Manel Esteller, Jesús García-Foncillas, E. Andion, Steven N. Goodman, O. F. Hidalgo, V. Vanaclocha, S. Baylin, James G. Herman. New England Journal of Medicine, 2000

2,255 citations recorded by the source corpus.

Subfields: Genetics, Molecular Biology, Pharmaceutical Science

View Paper: https://www.semanticscholar.org/paper/17b9ba9d48685f12bacd58d43aad26c154b22db9

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Genetics

1. Manel Esteller
2. S. Baylin
3. Peter W. Laird
4. Peter A. Jones
5. C. June
6. B. Levine
7. Hui Shen
8. Michael Weller

In Molecular Biology

1. Manel Esteller
2. S. Baylin
3. Peter A. Jones
4. Peter W. Laird
5. Hui Shen
6. J. Herman
7. Partha M. Das
8. R. Singal

In Pharmaceutical Science

1. S. Baylin
2. Manel Esteller

Citations in the corpus

• Epigenetic Determinants of Cancer. (2016, background): “Tumors in which O(6)MGMT is silenced in association with DNA methylation changes are more sensitive to alkylating therapy because the repair gene is not available to remove guanosine adducts from the genome (Esteller et al. 2000; Hegi et al. 2005).”
• DNA methylation and cancer. (2004, background): “promoter region of the DNA repair gene MGMT increased the sensitivity of gliomas to alkylating agents.(54) In another”
• Glioblastoma: pathology, molecular mechanisms and markers (2015, background): “A number of clinical trials and cohort studies have shown that promoter methylation of the MGMT gene is associated with prolonged progression-free and overall survival in patients who were treated with alkylating agents [41, 60, 61, 65, 172].”
• Glioma Subclassifications and Their Clinical Significance (2017, methodology): “MGMT promoter methylation is seen in approximately 40% of all GBMs [8] and can be measured through various methodologies, such as methylation microarray or bisulfate sequencing.”
• Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network. (2009, background): “MGMT promoter hypermethylation is associated with prolonged progression-free survival (PFS) and overall survival (OS) in patients with glioblastoma treated with alkylating agents such as nitrosoureas or temozolomide.(10-13) To systematically investigate the prognostic significance of molecular genet”
• CpG island hypermethylation and tumor suppressor genes: a booming present, a brighter future (2002, methodology): “…hypermethylation, the p15INK4b/p14ARF/p16INK4a locus (Herman et al., 1995; Merlo et al., 1995; Gonzalez-Zulueta et al., 1995; Robertson and Jones, 1999; Esteller et al., 2000b; Herman et al., 1996b) (Figure 3), we can consider that it behaves like a gene (INK4a/ARF) with two different promoters.”
• MGMT promoter methylation in malignant gliomas: ready for personalized medicine? (2010, background): “prognostic factor for outcome in patients with newly diagnosed glioblastoma, and is a powerful predictor of response to alkylating chemotherapy (Table 2).(10,11,13,38,40,41) The 2”